Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.37 |
| ▸ | FNTB | P49356 | 3/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.35 |
| ▸ | ATXN2 | Q99700 | 5/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11900910 | 1.00 | FNTA (0.37) | FNTAFNTBPGGT1BENPP2ATXN2 | |
| SCHEMBL11962599 | 0.94 | FNTA (0.35) | FNTAFNTBPGGT1BENPP2ATXN2 | |
| SCHEMBL17901196 | 0.90 | FNTA (0.34) | FNTAFNTBPGGT1BENPP2ATXN2 | |
| SCHEMBL1670770 | 0.90 | PDE5A (0.33) | PDE5APTGDR2S1PR1 | |
| SCHEMBL11899288 | 0.89 | ENPP2 (0.36) | FNTAFNTBPGGT1BENPP2ATXN2 | |
| SCHEMBL11899289 | 0.89 | ENPP2 (0.36) | FNTAFNTBPGGT1BENPP2ATXN2 | |
| SCHEMBL11899245 | 0.89 | ENPP2 (0.44) | FNTAFNTBPGGT1BENPP2ATXN2 | |
| SCHEMBL11898882 | 0.89 | ENPP2 (0.44) | FNTAFNTBPGGT1BENPP2ATXN2 | |
| SCHEMBL11962602 | 0.88 | ENPP2 (0.35) | FNTAFNTBPGGT1BENPP2ATXN2 | |
| SCHEMBL11962574 | 0.86 | ENPP2 (0.44) | ENPP2ATXN2KCNH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552001-B2 | Sulfoxide derivatives for the treatment of tumors | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8552001-B2 | Sulfoxide derivatives for the treatment of tumors | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8552001-B2 | Sulfoxide derivatives for the treatment of tumors | MERCK PATENT GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20120202827-A1 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202827-A1 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202827-A1 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS | Merck Patent Gesellschaft mit beschrankter Hafung (DE) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202827-A1 | SULFOXIDE DERIVATIVES FOR THE TREATMENT OF TUMORS | TP53, MGMT, VHL | FNTA 3813/4885FNTB 2233/4885PGGT1B 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.